18-chloro-octadecan-1-ol | 96752-02-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 18-chloro-octadecan-1-ol
• 英文别名: 18-Chlor-octadecan-1-ol；Chlorostearyl alcohol；18-chlorooctadecan-1-ol
• CAS: 96752-02-2
• 化学式: C₁₈H₃₇ClO
• 分子量: 304.944
• InChiKey: TWPCYNMUISVBAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.1
• 重原子数：
  20
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  18-chloro-octadecan-1-ol 在 氯化亚砜 、 苯乙酮 、 sodium iodide 、 苯 作用下， 生成 thiacyclononadecane
  参考文献：
  名称：

  Familial Head and Neck Cancer: Molecular Analysis of a New Clinical Entity

  摘要：

  AbstractObjective The tumor suppressor gene p16 encodes a cyclin‐dependent kinase inhibitor that normally inhibits cell proliferation by causing a G1 cell cycle arrest. The p16 gene is frequently mutated in a variety of somatic tumors, as well as in familial melanoma and familial pancreatic carcinoma. We identified a family with a high incidence of head and neck squamous cell carcinoma (HNSCC) and melanoma. Molecular analyses of the p16 gene locus in blood and tumor DNA from this family was performed to determine whether an association between germline p16 gene mutation and HNSCC exists.Study Design Molecular pedigree analyses.Methods Exon 2 of p16 was polymerase chain reaction amplified from blood, tumor, or nontumor DNA isolated from affected and unaffected members, then directly sequenced and compared with consensus p16 sequence. Cell cycle position of cells expressing wild‐type or mutant p16 was determined by flow cytometry.Results Molecular analyses revealed a nonfunctional germline point mutation within exon 2 of the p16 gene that encodes a mutant p16 protein substituting proline at amino acid position 87 for the wild‐type arginine (p16R87P). Relative to wild‐type p16, p16R87P lost ability to cause a growth arrest following ectopic expression. The mutant (p16R87P) allele segregated with cancer predisposition in tested family members, and analyses of HNSCC tumor tissues demonstrated universal loss of wild‐type allele.Conclusions Significance of the mutant p16 (p16R87P) in HNSCC tumorigenesis is strongly suggested by its loss of cell cycle arrest activity and its retention in tumor tissue with simultaneous loss of the wild‐type allele. Further, the germline p16 mutation segregated with cancer predisposition within the family. In aggregate, these data suggest that there is a direct causal relationship between the germline p16 mutation in this family and HNSCC tumorigenesis. Based on our observations, the spectrum of familial cancers associated with p16 mutations should include a new clinical entity, familial HNSCC.

  DOI：

  10.1097/00005537-200209000-00010
• 作为产物：
  描述：

  十八烷二酸二甲酯 在 盐酸 、 copper oxide-chromium oxide 、 水 、 Petroleum ether 作用下， 255.0 ℃ 、12.26 MPa 条件下， 生成 18-chloro-octadecan-1-ol
  参考文献：
  名称：

  Toxic Fluorine Compounds. III.¹ ι-Fluoroalcohols

  摘要：

  DOI：

  10.1021/jo01113a006

文献信息

• 135. Derivatives of the aliphatic glycols. Part IV
  作者：G. M. Bennett、Herbert Gudgeon

  DOI：10.1039/jr9380001679

  日期：——
• Bennett; Gudgeon, Journal of the Chemical Society, 1938, p. 1681
  作者：Bennett、Gudgeon

  DOI：——

  日期：——
• DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS-THERAPEUTIC SAMS
  申请人：Agrawal C. Mauli

  公开号：US20090123516A1

  公开（公告）日：2009-05-14

  Disclosed are medical devices comprising one or more surfaces, one or more SAM molecules attached to the one or more surfaces of the medical device, and one or more therapeutic agents attached to the one or more self-assembled monolayer molecules. Also disclosed are medical devices comprising one or more surfaces, one or more self-assembled monolayer molecules attached to the one or more surfaces of the medical device, one or more linkers comprising a first functional group and a second functional group, the first functional group attached to the self-assembled monolayer molecule and a therapeutic agent attached to the second functional group. The therapeutic agent may be attached to the SAM molecule via a linker. The present invention also concerns methods of administering a therapeutic agent to a subject, comprising contacting the subject with one of the medical devices set forth herein.
• US4067877A
  申请人：——

  公开号：US4067877A

  公开（公告）日：1978-01-10
• [EN] DRUG DELIVERY FROM IMPLANTS USING SELF-ASSEMBLED MONOLAYERS - THERAPEUTIC SAMS<br/>[FR] LIBERATION DE MEDICAMENTS PAR DES IMPLANTS COMPRENANT DES MONOCOUCHES AUTO-ASSEMBLEES (SAM) SAM THERAPEUTIQUES
  申请人：UNIV TEXAS

  公开号：WO2007019478A2

  公开（公告）日：2007-02-15

  [EN] Disclosed are medical devices comprising one or more surfaces, one or more SAM molecules attached to the one or more surfaces of the medical device, and one or more therapeutic agents attached to the one or more self-assembled monolayer molecules. Also disclosed are medical devices comprising one or more surfaces, one or more self-assembled monolayer molecules attached to the one or more surfaces of the medical device, one or more linkers comprising a first functional group and a second functional group, the first functional group attached to the self-assembled monolayer molecule and a therapeutic agent attached to the second functional group. The therapeutic agent may be attached to the SAM molecule via a linker. The present invention also concerns methods of administering a therapeutic agent to a subject, comprising contacting the subject with one of the medical devices set forth herein.
  [FR] L'invention concerne des dispositifs médicaux comprenant une ou plusieurs surfaces, une ou plusieurs molécules SAM attachées à une ou plusieurs surfaces du dispositif médical, et un ou plusieurs agents thérapeutiques fixés sur les molécules de la ou des monocouches auto-assemblées. L'invention concerne en outre des dispositifs médicaux comprenant une ou plusieurs surfaces, une ou plusieurs molécules de monocouche auto-assemblée fixées à la surface ou aux surfaces du dispositif médical, un ou plusieurs lieurs comprenant un premier groupe fonctionnel et un second groupe fonctionnel, le premier groupe fonctionnel étant attaché à la molécule de la monocouche auto-assemblée, et un agent thérapeutique attaché au second groupe fonctionnel. L'agent thérapeutique peut être fixé sur la molécule SAMS par l'intermédiaire d'un lieur. L'invention porte également sur des procédés d'administration d'un agent thérapeutique à un sujet consistant appliquer un dispositif médical du type décrit à un sujet.